Author

R. Gence

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:development & morphogenesis· 1 Organism:mouse· 1

Frequent Co-Authors

A. Casanova· 1 shared A. Diz-Munoz· 1 shared A. Maraver· 1 shared A. Metais· 1 shared A. Pradines· 1 shared B. Raynaud-Messina· 1 shared C. Blin-Wakkach· 1 shared C. Delahaye· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Casanova

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Moesin controls cell-cell fusion and osteoclast function

O. Dufrancais, P. Verdys, M. Plozza, A. Metais, M. Juzans, T. Sanchez, M. Bergert, J. Halper, C. J. Panebianco, R. Mascarau, R. Gence, G. Arnaud, M. Ben Neji, I. Maridonneau-Parini, V. Le Cabec, , C. Verollet

This study identifies moesin's role in osteoclast fusion and function, showing its impact on bone resorption and disease therapy.

bioRxiv · May 13, 2024 · PreprintCell Biology

Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC

S. Figarol, C. Delahaye, R. Gence, R. Asslan, S. Pagano, C. Tardy, J. Colinge, J.-P. Villemin, A. Maraver, I. Ferrer, L. Paz-Ares, I. Lajoie-Mazenc, E. Clermont, A. Casanova, A. Pradines, , G. Favre

This study identifies early escapers as a rare cell population resistant to EGFR-TKi and shows that tipifarnib overcomes this resistance by targeting Rho/ROCK pathway and preventing relapse.

bioRxiv · Apr 1, 2022 · PreprintCancer Biology